You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for its content.
The list price does not represent the actual price you will pay for a medicine.
The link between list price and what you pay can be confusing. With medicines, a lower list price is no guarantee of a lower out-of-pocket cost.
If you have prescription drug coverage, your insurance company is the best resource to understand your out-of-pocket cost.
if you do not have prescription drug insurance or if your medicine is not covered by your insurance, talk to a pharmacist where you purchase your medicine to better understand your cost.
IQVIA LAAD Rx, IQVIA US Market Access Analytic Solutions analysis. Accessed on October 25, 2024. Based on analysis of national pharmacy level data of commercially and Medicare insured patients who filled their prescription at the pharmacy between October 2023 - September 2024. The analysis includes only claims that were paid, or for which price was accepted by patients after using insurance and/or any copay cards, discount cards or other offers, and for which data about the transaction was available. The analysis consisted of fill data for TRELEGY ELLIPTA (fluticasone furoate, umeclidinium and vilanterol inhalation powder).